

Dear members of the ELN,

This Saturday, the 2012 ASH Annual Meeting and Exposition starts in Atlanta. In this issue we prepared some information on ELN meetings that take place in the course of the congress and other interesting news connected to ASH and - of course - to the ELN.

We would like to take the opportunity to thank all members for their support in 2012 and send you our very best wishes for the forthcoming holidays and for a good start to the new year.

Kind regards,

European Leukemia Information Center - ELIC

■ **ELN Breakfast Meeting and WP meetings at the ASH 2012**

On Sunday December 9th the ELN breakfast meeting takes place at Hilton Atlanta – Grand Ballroom East. The agenda of this meeting as well as of different work package meetings is now available on the website. ▶ [agenda of the ELN breakfast meeting](#)

■ **The ELN website is in compliance with the HONcode**

As in previous years the website of the European LeukemiaNet successfully passed the quality check of the Health On the Net Foundation (HON). The HONcode certificate is awarded to websites that coincide with the 8 principles of the HONcode of Conduct (authoritative, complementarity, privacy, attribution, justifiability, transparency, financial disclosure and advertising policy). For detailed information on this quality label please click on the HONcode logo on the ▶ [ELN homepage](#).

■ **Renaming of WP13**

The ELN work package 13 “Gene profiling” was renamed. Due to new methods and technologies WP13 will in future be referred to as “Next generation sequencing”. For more information on WP13 please have a look at ▶ [Next generation sequencing](#).

■ **ASH: Summary of oral presentations**

In order to provide all network members with information on “advances in the field” ELIC is aiming to publish summaries on the most important ASH abstracts of oral presentations on the therapy/treatment of leukemia in cooperation with the respective WP leaders. These overviews will soon be available on the website and will also be published in the upcoming Information Letter.

■ **Publications from the Network (selected)**

- ▶ Bornhäuser M et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. *Lancet Oncol.* 2012 Oct;13(10):1035-44.
- ▶ Büchner T et al. Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm-- Combined Prospective Analysis by the German AML Intergroup. *J Clin Oncol.* 2012 Oct 10;30(29):3604-10.
- ▶ Cornelissen JJ et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. *Nat Rev Clin Oncol.* 2012 Oct;9(10):579-90.
- ▶ Coscia M et al. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. *Blood.* 2012 Oct 18;120(16):3271-9.
- ▶ Cross NC et al. Standardized definitions of molecular response in chronic myeloid leukemia. *Leukemia.* 2012 Oct;26(10):2172-5.
- ▶ Emanuel RM et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. *J Clin Oncol.* 2012 Nov 20;30(33):4098-103.
- ▶ Gaidano G et al. Molecular pathogenesis of chronic lymphocytic leukemia. *J Clin Invest.* 2012 Oct 1;122(10):3432-8.

- ▶ Gowin K et al. Experience with pegylated interferon α -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. *Haematologica*. 2012 Oct;97(10):1570-3.
- ▶ Grossmann V et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. *Blood*. 2012 Oct 11;120(15):2963-72.
- ▶ Hospital MA et al. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. *Bone Marrow Transplant*. 2012 Nov;47(11):1436-41.
- ▶ Larson RA et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. *Leukemia*. 2012 Oct;26(10):2197-203.
- ▶ Meggendorfer M et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). *Blood*. 2012 Oct 11;120(15):3080-8.
- ▶ Poletto V et al. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. *Blood*. 2012 Oct 11;120(15):3112-7.
- ▶ Rea D et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. *Leukemia*. 2012 Oct;26(10):2254-9.
- ▶ Ribera JM et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. *Br J Haematol*. 2012 Oct;159(1):78-81.
- ▶ Ribera JM et al. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era: comparison of two prospective parallel protocols. *Br J Haematol*. 2012 Nov;159(4):485-8.
- ▶ Ringdén O et al. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. *J Intern Med*. 2012 Nov;272(5):472-483.
- ▶ Ruutu T et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2012 Nov;47(11):1459-64.
- ▶ Schnittger S et al. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. *Haematologica*. 2012 Oct;97(10):1582-5.
- ▶ Schnittger S et al. Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. *Genes Chromosomes Cancer*. 2012 Oct;51(10):910-24.
- ▶ Schuurhuis GJ et al. The adverse prognosis for acute myeloid leukemia patients with superior autologous stem cell mobilization. *Leuk Res*. 2012 Nov;36(11):1323-4.
- ▶ Schwaab J et al. Activating CBL mutations are associated with a distinct MDS/MPN phenotype. *Ann Hematol*. 2012 Nov;91(11):1713-20.
- ▶ Tang M et al. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. *Haematologica*. 2012 Oct;97(10):1553-61.
- ▶ Vey N et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. *Blood*. 2012 Nov 22;120(22):4317-23.
- ▶ Wandt H et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. *Lancet*. 2012 Oct 13;380(9850):1309-16.

■ New trials in the ELTR

HCT vs CT Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission

B1931022 An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

■ ■ European Leukemia Information Center - ELIC

Dr. Nicola Gökbuget, Dr. Sina Hehn

Johann Wolfgang Goethe University Hospital | Department of Medicine II

Theodor-Stern-Kai 7 | 60590 Frankfurt am Main, Germany

+49 (0)69 6301 6365 | ELIC@em.uni-frankfurt.de | www.leukemia-net.org